This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
MANTRA-PAF was a randomized phase 3 parallel-group trial evaluating radiofrequency ablation versus antiarrhythmic drug treatment in patients with atrial fibrillation. The registered primary endpoint was atrial fibrillation burden measured over two years.
| Feature | MANTRA-PAF |
|---|---|
| Trial acronym | MANTRA-PAF |
| ClinicalTrials.gov identifier | NCT00133211 |
| Phase | Phase 3 |
| Status | Completed |
| Condition | Atrial Fibrillation |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | None |
| Primary purpose | Treatment |
| Enrollment | 294 |
| Number of arms | 2 |
| Lead sponsor | Danish Heart Foundation |
| Start date | 2005-09 |
| Primary completion date | 2014-09 |
2. Clinical Question
The central clinical question was whether radiofrequency ablation should be compared with antiarrhythmic drug treatment in patients with atrial fibrillation using atrial fibrillation burden over two years as the registered primary endpoint.
Population
Patients enrolled in the MANTRA-PAF phase 3 study with the condition listed in the registry as atrial fibrillation.
Intervention
Radiofrequency ablation (procedure).
Comparator
Antiarrhythmic drug treatment, as specified in the registered trial title.
Primary question
How does the randomized comparison affect atrial fibrillation burden over two years?
3. Trial Design
Radiofrequency ablation
- Radiofrequency ablation
- Procedure-based intervention
- Randomized comparison within a parallel-group phase 3 design
Antiarrhythmic drug treatment
- Antiarrhythmic drug treatment
- Drug-treatment comparator
- Randomized comparison within a parallel-group phase 3 design
The combination of randomized allocation and a parallel design provides the basic structure for comparing the two treatment strategies. Because the study was unmasked, interpretation of outcomes that involve subjective assessment can be more vulnerable to knowledge of treatment assignment than in a blinded trial. The primary endpoint, however, is expressed as atrial fibrillation burden, which is fundamentally a quantitative outcome rather than a simple binary clinical event.
4. Endpoints
| Endpoint | Registry definition / time frame | Statistical role |
|---|---|---|
| Atrial fibrillation burden | Atrial fibrillation burden; two years | Primary endpoint |
The registry identifies atrial fibrillation burden as the primary endpoint and specifies a two-year time frame. The registry record does not provide a more detailed operational definition of burden in the information available here, such as a particular measurement window, transformation, monitoring schedule, or prespecified threshold.
5. Planned Analysis
No results are posted on ClinicalTrials.gov for the registered primary endpoint. The registry identifies atrial fibrillation burden over two years as the primary outcome, but the record does not provide a posted statistical analysis with an effect estimate, confidence interval, or p-value.
For a randomized two-arm trial with a quantitative atrial fibrillation-burden endpoint, the primary analysis would normally compare the distribution of burden between randomized groups at the prespecified two-year assessment. The exact method should follow the way burden was defined and collected.
| Statistical issue | Typical approach | Why it matters |
|---|---|---|
| Two-group comparison | Compare the primary burden measure between randomized treatment groups using a prespecified two-group model or test. | The treatment contrast should preserve the randomized comparison. |
| Continuous burden | A linear-model or ANCOVA-type analysis may be appropriate when the outcome has suitable distributional properties. | Adjustment can improve precision when prespecified baseline measurements are available. |
| Skewed burden | A transformation, rank-based method, or other distribution-appropriate model may be considered. | Burden measurements can be concentrated near zero and may not be approximately normal. |
| Repeated monitoring | A longitudinal or mixed-effects model may be appropriate when multiple burden measurements contribute to the endpoint. | Repeated observations within a participant are correlated. |
| Missing observations | The prespecified missing-data strategy should define how incomplete monitoring or incomplete two-year assessments are handled. | Different assumptions about missingness can change the estimated treatment contrast. |
| Effect estimation | A treatment-group difference, ratio, or another prespecified contrast should be accompanied by a confidence interval. | An effect estimate describes magnitude, while the interval describes precision. |
The most important statistical principle is that the analysis should be specified before examining the treatment comparison. With a quantitative primary endpoint, the treatment effect should be expressed in a form that matches the endpoint's measurement scale and clinical meaning.
6. Statistical Methodology
Randomized comparison
Randomization is the foundation of the primary treatment comparison. When participants are analyzed according to their randomized assignment, differences between treatment groups can be interpreted within the causal framework created by randomization, subject to losses to follow-up, protocol deviations, missing outcome information, and other departures from the intended analysis.
Quantitative endpoint analysis
Atrial fibrillation burden differs from a conventional binary endpoint such as “atrial fibrillation recurrence: yes or no.” A burden endpoint contains information about the amount of atrial fibrillation observed during the relevant monitoring period. The appropriate statistical model therefore depends on the precise definition and measurement process.
A difference is only one possible effect scale. If burden is naturally interpreted as a proportion or percentage, a ratio or other scale may instead be prespecified. The clinically meaningful effect scale should be selected before the primary analysis.
Analysis of covariance
If a baseline measure related to the two-year burden outcome was collected, ANCOVA or a related linear model could improve statistical precision by accounting for baseline prognostic information. The important distinction is between adjustment that was prespecified and exploratory adjustment introduced after observing the results.
Longitudinal analysis
If atrial fibrillation burden was observed repeatedly during follow-up rather than only once at two years, a longitudinal model could use those repeated measurements while accounting for within-participant correlation. Mixed-effects models are one common framework for this situation.
Confidence intervals
A treatment-effect estimate should ideally be accompanied by a confidence interval. The estimate describes the observed treatment contrast, while the confidence interval describes the statistical precision associated with that estimate under the selected model and sampling framework.
Multiplicity
The registry information available here identifies one primary endpoint: atrial fibrillation burden at two years. No additional multiplicity strategy is specified in the record information available here. If multiple secondary endpoints, repeated primary analyses, or multiple treatment contrasts were formally tested, the statistical analysis plan would need to specify how the familywise type I error rate was controlled.
7. Statistical Methods Explained
Why is atrial fibrillation burden different from a simple recurrence endpoint?
A recurrence endpoint generally classifies a participant according to whether an event occurred. A burden endpoint instead attempts to quantify how much atrial fibrillation occurred during a defined period. Two participants can both experience atrial fibrillation while having very different burdens, so reducing the outcome to recurrence alone can discard information.
Why does the distribution of burden matter?
Quantitative burden measurements may be asymmetric, particularly if many participants have low values and a smaller number have substantially higher values. A conventional mean-based model may be reasonable in some settings, but its assumptions should be checked against the actual endpoint distribution. Transformation or alternative models can be considered when those assumptions are not appropriate.
Why might ANCOVA be used?
ANCOVA can compare treatment groups on a follow-up quantitative outcome while adjusting for a prespecified baseline measurement. If baseline burden is strongly related to follow-up burden, this can reduce residual variability and increase precision without changing the randomized treatment comparison.
Why might a mixed-effects model be useful?
If burden is measured repeatedly, observations from the same participant are not independent. A mixed-effects model can represent both the treatment comparison and the correlation among repeated observations. The model can also describe change over time when that is part of the prespecified analysis.
What does a treatment-group difference mean?
A difference such as “RFA minus drug treatment” describes the estimated separation between the two randomized groups on the burden scale. The direction of the difference depends on how the endpoint is coded. A negative difference would indicate lower burden in the RFA group under that coding; it would not by itself establish the clinical importance of the difference.
Why is the confidence interval important?
A point estimate alone does not show how precisely the treatment effect was estimated. A confidence interval provides a range of values compatible with the statistical model and data under the chosen confidence level. A narrow interval indicates greater statistical precision than a wide interval, although precision and clinical importance are different concepts.
8. Interpreting the Two-Year Primary Endpoint
The registered primary endpoint is atrial fibrillation burden at two years. Because no statistical result for this endpoint is posted in the ClinicalTrials.gov record, there is no reported treatment-effect estimate, confidence interval, or p-value to interpret here.
The key statistical question would be whether the prespecified comparison demonstrated a meaningful difference in burden between the randomized radiofrequency-ablation and antiarrhythmic-drug groups, with the magnitude and uncertainty of that difference reported on an appropriate effect scale.
What the endpoint can measure
A burden endpoint can capture differences in the amount of atrial fibrillation experienced during follow-up rather than merely whether recurrence occurred.
What the endpoint does not automatically show
A difference in atrial fibrillation burden does not automatically quantify effects on every other clinical outcome. Those questions require separately defined endpoints.
What a p-value would mean
If a formal hypothesis test were reported, its p-value would quantify evidence against the specified null hypothesis under the selected statistical model. It would not measure the size or clinical importance of the treatment effect.
What a confidence interval would add
A confidence interval would show the precision of the estimated treatment contrast and would help distinguish a precise estimate from one with substantial statistical uncertainty.
9. Missing Data and Measurement Considerations
Quantitative atrial fibrillation burden requires adequate observation of the underlying rhythm over the relevant assessment period. Missing monitoring information can therefore be particularly important: incomplete observation can affect both the calculated burden and the comparability of measurements between treatment groups.
A rigorous statistical analysis would prespecify how incomplete monitoring, early withdrawal, loss to follow-up, and other missing measurements are handled. The choice should be linked to a plausible mechanism for missingness rather than treated as a purely computational problem.
| Issue | Statistical question |
|---|---|
| Incomplete monitoring | Was the observed monitoring time sufficient to characterize the participant's burden? |
| Withdrawal before two years | Does the reason for withdrawal relate to treatment or subsequent atrial fibrillation status? |
| Unequal follow-up | Can burden be compared directly when participants contribute different amounts of observation? |
| Missing repeated measurements | Is the missingness related to previous burden, treatment, symptoms, or other observed factors? |
| Analysis population | Are participants retained according to randomized assignment for the primary comparison? |
These issues illustrate why an apparently simple quantitative endpoint can require a detailed statistical analysis plan. The measurement process is part of the statistical definition of the outcome.
10. Randomization and Analysis Population
The study is registered as randomized, with two parallel arms and 294 enrolled participants. For the primary efficacy comparison, an intention-to-treat framework would generally analyze participants according to their randomized treatment assignment, regardless of subsequent treatment changes, provided that the prespecified analysis population follows that principle.
The purpose of retaining the randomized assignment is to preserve the comparability created by randomization. Excluding participants after randomization can introduce selection if exclusion is related to treatment or outcome.
Per-protocol or as-treated analyses can provide complementary information in some trials, but they answer somewhat different questions and can be more susceptible to post-randomization selection. The registry information available here does not specify an alternative efficacy analysis population.
11. Non-Blinded Design
The registry lists the masking status as none. This is an important design characteristic because participants and investigators can know which treatment strategy was assigned.
For an objectively measured quantitative endpoint, lack of masking does not automatically invalidate the treatment comparison. It does, however, create potential pathways for treatment knowledge to influence behavior, monitoring, treatment decisions, reporting, or other aspects of outcome ascertainment. The practical importance depends on exactly how atrial fibrillation burden was measured.
12. Two-Year Time Frame
The registry specifies two years as the time frame for the primary atrial fibrillation burden endpoint. This creates a clearly defined horizon for the primary treatment comparison.
Study start
The registered start date is September 2005.
Primary endpoint horizon
Atrial fibrillation burden is registered as the primary endpoint with a two-year time frame.
Primary completion
The registered primary completion date is September 2014.
The distinction between the study's overall completion timeline and the primary endpoint's two-year assessment window is important. A trial can have a later administrative completion date while its primary outcome is defined at an earlier follow-up point.
13. Statistical Interpretation of Treatment Effects
The primary statistical result should report a treatment effect on a scale appropriate to atrial fibrillation burden. A mean difference, adjusted mean difference, ratio, or another contrast can each be valid in the appropriate setting. The choice should be determined by the endpoint definition and prespecified analysis rather than by which scale produces the most favorable-looking result.
The treatment-effect estimate should be accompanied by a confidence interval. This allows readers to distinguish the estimated magnitude from the uncertainty surrounding that estimate. A confidence interval is not a range containing the effects experienced by individual participants.
A p-value, if reported, would address the compatibility of the observed data with a prespecified null hypothesis under the statistical model. It would not tell the reader how large or clinically important the treatment effect is. Effect size and uncertainty should therefore remain central to interpretation.
The statistical question is whether the randomized treatment groups differ in atrial fibrillation burden. The clinical question is whether the magnitude of any difference is meaningful to patients and clinicians. Those questions are related but are not interchangeable.
14. What Would Constitute a Complete Primary Analysis?
A complete statistical presentation of the registered primary endpoint would normally contain several complementary pieces of information rather than a single significance test.
| Component | Purpose |
|---|---|
| Sample size by randomized group | Shows the information contributing to the comparison. |
| Definition of atrial fibrillation burden | Establishes exactly what quantity was analyzed. |
| Descriptive burden statistics | Shows the observed distribution in each treatment group. |
| Treatment-effect estimate | Quantifies the difference between randomized strategies. |
| Confidence interval | Describes statistical precision. |
| Hypothesis test | Assesses evidence against the prespecified null hypothesis. |
| Analysis population | Clarifies which randomized participants contributed to the primary analysis. |
| Missing-data approach | Explains how incomplete outcome information was handled. |
Without these elements, a reader cannot fully judge the magnitude, precision, and assumptions underlying the primary treatment comparison. The registry record available here does not post such a formal statistical analysis.
15. Important Limitations and Interpretation Issues
- No posted primary results: the ClinicalTrials.gov record does not post a statistical result for the registered primary endpoint of atrial fibrillation burden.
- Limited endpoint detail: the record identifies atrial fibrillation burden and a two-year time frame but does not provide the more detailed measurement definition needed to identify a single preferred statistical model.
- Unmasked design: the registry lists no masking, which can create potential for treatment knowledge to affect aspects of treatment, monitoring, reporting, or outcome assessment.
- Missing-data sensitivity: quantitative burden measurements can be sensitive to incomplete rhythm monitoring or incomplete follow-up.
- Distributional assumptions: burden outcomes may be skewed or bounded, so a standard normal-theory comparison should not be assumed without examining the endpoint distribution.
- Repeated measurements: if burden was measured at multiple time points, within-participant correlation must be accounted for rather than treating all observations as independent.
- Analysis population: maintaining randomized treatment assignment is important for the principal treatment comparison, while post-randomization exclusions can alter the estimand.
- Clinical interpretation: a statistically detectable difference in burden would still need to be considered in relation to the magnitude of the difference and its clinical relevance.
16. Why This Trial Matters Statistically
MANTRA-PAF is a useful teaching case because its primary endpoint illustrates a statistical problem that differs from the familiar survival-analysis framework used in many clinical trials. The registered outcome is not simply whether atrial fibrillation recurred. It is atrial fibrillation burden over two years, which requires attention to measurement, distribution, repeated observation, and missingness.
| Concept | How it appears in MANTRA-PAF |
|---|---|
| Randomization | Participants were randomly allocated in a phase 3 treatment trial. |
| Parallel-group design | Two treatment arms were evaluated in parallel. |
| Quantitative endpoint | The primary outcome is atrial fibrillation burden. |
| Time horizon | The registered primary endpoint is assessed over two years. |
| Outcome distribution | Burden may require methods appropriate to bounded or skewed quantitative data. |
| Longitudinal measurement | Repeated monitoring, if used to construct burden, creates within-participant dependence. |
| Missing data | Incomplete monitoring can affect the calculation and comparability of burden. |
| Unmasked treatment | The registry lists no masking, making measurement and behavioral pathways relevant to interpretation. |
| Effect size | The treatment comparison should be expressed on a clinically interpretable burden scale. |
| Confidence interval | Precision should accompany the primary treatment-effect estimate. |
17. Statistical Concepts in This Trial
The MANTRA-PAF design provides a focused example of how randomized clinical-trial statistics change when the primary endpoint is a quantitative burden measure rather than a conventional binary or time-to-event endpoint.
Randomized treatment comparison
The fundamental comparison is between the two randomized treatment strategies rather than between participants selected after treatment begins.
Quantitative outcomes
A burden endpoint retains more information than a simple recurrence indicator but requires attention to its measurement scale.
Repeated measures
When multiple observations contribute to a participant-level outcome, statistical models must account for within-person correlation.
Missing data
Incomplete monitoring can change the amount of information available for estimating burden.
Confidence intervals
Uncertainty around the treatment contrast is essential for interpreting the precision of the result.
Unmasked trials
Randomization and masking address different sources of bias; a randomized trial can still have important measurement considerations when treatment is known.
18. Planned Analysis: A Statistical Walkthrough
Step 1: Define the estimand
The primary question should identify the treatment strategies being compared, the enrolled population, the two-year time horizon, and the atrial fibrillation burden outcome. The estimand should be defined before selecting the final statistical model.
Step 2: Describe the endpoint
The analyst should establish whether atrial fibrillation burden is represented as a proportion of monitored time, a duration, a count-derived measure, or another quantitative summary. That definition determines the appropriate statistical scale.
Step 3: Examine the distribution
Descriptive summaries and graphical assessment should determine whether the burden outcome is approximately symmetric, strongly skewed, zero-heavy, bounded, or otherwise unsuitable for a simple normal-theory model.
Step 4: Specify the primary contrast
The treatment contrast should be defined explicitly. Depending on the measurement scale, this could be a difference in mean burden, an adjusted mean difference, a ratio, or another prespecified measure.
Step 5: Account for repeated observations
If the endpoint is constructed from repeated measurements, the analysis should account for the correlation between measurements from the same participant. A mixed-effects or related longitudinal framework may be appropriate when the raw repeated measurements themselves are analyzed.
Step 6: Address incomplete data
The missing-data strategy should be linked to the timing and reason for missingness. Sensitivity analyses can be valuable when conclusions depend materially on assumptions about observations that were not collected.
Step 7: Report effect size and uncertainty
The final presentation should show the treatment-effect estimate, its confidence interval, and the prespecified hypothesis-test result if one was used. These should be interpreted together rather than relying on statistical significance alone.
19. Trial Timeline
Start date
The ClinicalTrials.gov record lists September 2005 as the study start date.
Randomized treatment comparison
The study is registered as a phase 3 randomized, parallel-group treatment trial with two arms and no masking.
Primary outcome horizon
The registered primary endpoint is atrial fibrillation burden measured over two years.
Primary completion date
The registered primary completion date is September 2014.
20. Clinical Interpretation vs Statistical Interpretation
Statistical interpretation
The trial's registered primary comparison concerns atrial fibrillation burden over two years between randomized radiofrequency-ablation and antiarrhythmic-drug treatment groups. The appropriate analysis should quantify the treatment contrast and its uncertainty on a scale suited to the burden endpoint.
Clinical interpretation
The clinical meaning of a treatment difference depends on how large the change in atrial fibrillation burden is, how reliably burden was measured, and whether that magnitude represents an outcome that is meaningful to patients.
Keeping these two levels of interpretation separate is particularly important for quantitative endpoints. Statistical evidence concerns the treatment contrast and uncertainty; clinical interpretation concerns the magnitude and relevance of that contrast.
21. Sources
- ClinicalTrials.gov: MANTRA-PAF, NCT00133211.
Continue through Clinical Biostats
Clinical trial analysis connects study design, endpoint definition, statistical modeling, effect estimation, and interpretation.
22. Record Summary
MANTRA-PAF is a randomized phase 3 parallel-group trial with 294 enrolled participants comparing radiofrequency ablation with antiarrhythmic drug treatment for atrial fibrillation. Its registered primary endpoint is atrial fibrillation burden over two years. Statistically, the trial is especially useful for illustrating how the analysis of a quantitative burden endpoint depends on its precise measurement definition, distribution, repeated observations, missing-data structure, and choice of treatment-effect scale.
The strongest statistical presentation of such a trial would combine the randomized treatment contrast with an explicit definition of atrial fibrillation burden, appropriate descriptive statistics, a prespecified model or comparison, a confidence interval, and a transparent account of missing observations and analysis population. The ClinicalTrials.gov record does not post a formal statistical analysis or numerical result for the primary endpoint.